Anticancer Research · 2018 · 38 citations · 33 references
MedicineOncologyPharmacologyCancer PharmacologyCellular MetabolismChemotherapyCancer ChemopreventionCancer MetabolismGlioblastomaMetabolic ReprogrammingMetabolic Reprogramming In CancerMetabolism Of Anticancer AgentsAnticancer ActivityAnticancer ChemotherapyCancer Cell Proliferation InhibitionCell Cycle InhibitionGlioblastoma MetabolismTemozolomide TherapyTumor Cell MetabolismTumor Metabolism
Background/Aim: Several epidemiological studies have reported the chemopreventive potential of biochanin A, in cancer development and progression. We investigated the anticancer potential of combination of biochanin A and temozolomide against U-87 MG and T98 G [glioblastoma multiforme (GBM)] cells. Materials and Methods: We evaluated the effect of biochanin A and temozolomide treatment on cell viability, expression of survival proteins, cell cycle, cell metabolism and mitochondrial function. Results: Enhanced inhibitory effects of the combination treatment were observed on cell viability, expression of cell survival proteins EGFR, p-ERK, p-AKT, c-myc and MT-MMP1, and increased expression of the tumor suppressor, p-p53. Combination treatment also induced arrest in the G<sub>1</sub> phase of the cell cycle. A shift in the metabolic phenotype of cells from glycolytic to oxidative phosphorylation was observed on combination treatment and the permeabilized cells showed a significant impairment in complex IV activity. Conclusion: Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.
33
Genistein, a specific inhibitor of tyrosine-specific protein kinases.
Tetsu Akiyama, Junko Ishida, Shizue Nakagawa et al. · Journal of Biological Chemistry · 1987 · 3.7K citations · Full text
Paul D. Brown, Sunil Krishnan, Jann N. Sarkaria et al. · Journal of Clinical Oncology · 2008 · 275 citations · Full text
Medicine, Oncology, Pharmacotherapy +17